The in vitro bioavailability of anti-platelet peptides in collagen hydrolysate from silver carp (Hypophthalmichthys molitrix) skin.

Abstract

Previous animal experiments indicated collagen hydrolysates (CHs) intake decreased platelet release indicators in plasma and highlight potential applications as healthcare supplements to combat cardiovascular disease. The oligopeptides (GPR, GPRG, and GPRGP) have anti-platelet activities. However, it is still unclear whether they are bioactive compounds in CHs from silver carp skin. We investigated the bioavailability of oligopeptides using simulated gastrointestinal digestion and Caco-2 model. Anti-thrombotic activities, in vitro platelet aggregation and formation of platelet thrombus, were evaluated. They resisted gastrointestinal digestion and could be absorbed by Caco-2. Oligopeptides inhibited platelet aggregation induced by adenosine diphosphate and thrombin with IC50 of 0.160, 0.283, 0.251mg/ml and 0.714, 1.008, 0.917mg/ml for GPR, GPRG, and GPRGP, respectively. Oligopeptides prolonged the time of platelet thrombus and inhibited coagulation cascades, but CHs performed no bleeding side effect. These results confirmed that oligopeptides could be used as bioactive compounds of dietary supplements for pre-thrombotic to prevent thrombosis. PRACTICAL APPLICATIONS: Oligopeptides, GPR, GPRG, and GPRGP, derived from silver carp (Hypophthalmichthys molitrix) skin collagen, performed anti-thrombotic activities from their anti-platelet aggregation and anticoagulation activities. But the collagen hydrolysates containing these peptides had no side effect of bleeding in the mice model. Furthermore, this study investigated the bioavailability of these three bioactive peptides by the Caco-2 cells model. Thus, oligopeptides GPR, GPRG, and GPRGP are a potential index of bioactive compounds in the preparation of anti-thrombotic functional foods or healthcare supplements for people at the pre-thrombotic state.